Published March 1, 2022 | Version v1
Patent Open

Methods of treating cancers with CT45 targeted therapies

  • 1. University of Chicago
  • 2. Max Planck Institute

Contributors

Description

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Files

US11261223.pdf

Files (4.6 MB)

Name Size Download all
md5:ea6dd82a9374f182bc39bea34c1a2e2d
4.6 MB Preview Download

Additional details

Identifiers

Patent number
US 11261223 B2
Patent application number
US 201716300267 A
Other
oai:uchicago.tind.io:7381

Dates

Patent filed
2017-05-11

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine